ClinicalTrials.gg
CompletedNCT00461786Updated Dec 4, 2009Results posted

A Study of Single Agent Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer

A Phase 2 interventional study of pemetrexed in Ovarian Cancer and Peritoneal Cancer, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2009-12-04.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
51
Allocation
Non-randomized
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing pemetrexed in Ovarian Neoplasms — none open to participants now, none under way, none of them phase 3. Pemetrexed · Ovarian Neoplasms.

Enrollment
3rd of 12
51 · median 36
Started
2004
with 1 other
Phase 2
8 of 13
none open now
Registered
6th of 13
by date
Lead sponsor
4 of 13
Eli Lilly and Company

Among the 13 studies testing pemetrexed in Ovarian Neoplasms, this one is the 3rd largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2004, is one of 8 in phase 2, and was the 6th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

None of the 13 studies testing pemetrexed in Ovarian Neoplasms is open now. The open studies under Ovarian Neoplasms, anywhere →

About pemetrexed

Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing pemetrexed in Ovarian Neoplasms as a file.
02

Study summary

The primary purpose of this trial is to estimate the drug effect on tumors in patients with ovarian or primary peritoneal cancers. Patients will receive Pemetrexed every 21 days until disease progression or unacceptable toxicity. This medication will be given over 10 minutes and may be administered intravenously (IV), through a vein in your arm. Vitamin supplementation is a required part of this study.

03

Conditions studied

  • Ovarian Cancer
  • Peritoneal Cancer

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed recurrent or persistent disease ovarian epithelial or primary peritoneal cancer
  • Must have received 1 prior platinum-based (carboplatin, cisplatin, or another organoplatinum compound) chemotherapy regimen for primary disease. Patients who had not received prior paclitaxel may have received a second regimen that included paclitaxel
  • Treatment-free interval \< 6 months after prior platinum-based therapy OR progressed during platinum-based therapy
  • Not eligible for a higher priority Gynecologic Oncology Group (GOG) protocol (i.e., any active phase III GOG protocol for the same patient population)

Exclusion criteria

Exclusion Criteria:

  • Patients who have had prior therapy with pemetrexed
  • Patients with a history of other invasive , with the exception of non-melanoma skin cancer, are excluded if there is any evidence of other malignancy being present within the last five years. Patients are also excluded if their previous cancer treatment contraindicates this protocol therapy.
  • Patients who have received radiation to more than 25% of marrow
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    Pemetrexed

    Drug: pemetrexed

Interventions

  • 900 mg/m2, intravenous (IV), every 21 days, until disease progression

    Also known as: LY231514, Alimta

06

What researchers measure

Primary outcomes

  1. Tumor Response

    Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment. Complete response (CR) = disappearance of all target lesions; Partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions; Progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions; Stable disease (SD) = small changes that do not meet above criteria.

    Time frame: baseline to measured progressive disease (up to 44 months)

Secondary outcomes

  1. Number of Participants With Adverse Events by Grade

    Adverse events were graded using the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0) for defining and grading specific adverse events. A grading (severity) scale is provided for each adverse event term. Grades range from 0 (none) to 5 (death). The worst grade event per cycle is reported.

    Time frame: every 21-day cycle up to 5 year follow-up

  2. Duration of Response

    The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause.

    Time frame: time of initial response until documented tumor progression (up to 44 months)

  3. Progression-Free Survival

    Defined as the time from date of first dose to the first observation of disease progression, or death due to any cause.

    Time frame: baseline until documented tumor progression (up to 44 months)

  4. Overall Survival

    Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact.

    Time frame: baseline until death from any cause up to 5-year follow-up

07

Results

Posted Aug 24, 2009

Participant flow

Participant flow — Overall Study
MilestonePemetrexed
Started51
Completed48
Not completed3
Withdrew: Entry criteria not met2
Withdrew: Inevaluable (never treated)1

Outcome measures

PrimaryTumor Response

Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment. Complete response (CR) = disappearance of all target lesions; Partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions; Progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions; Stable disease (SD) = small changes that do not meet above criteria.

Time frame:
baseline to measured progressive disease (up to 44 months)
Reported as:
Number · participants
Tumor Response
participantsPemetrexed
Complete Response1
Partial Response9
Stable Disease17
Progressive Disease18
Inevaluable3
Statistical analysis
  • Pemetrexed · Overall response rate: 21 · 95% CI 10.5 to 35.0
SecondaryNumber of Participants With Adverse Events by Grade

Adverse events were graded using the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0) for defining and grading specific adverse events. A grading (severity) scale is provided for each adverse event term. Grades range from 0 (none) to 5 (death). The worst grade event per cycle is reported.

Time frame:
every 21-day cycle up to 5 year follow-up
Reported as:
Number · participants
Number of Participants With Adverse Events by Grade
participantsPemetrexed
Leukopenia - Grade 111
Leukopenia - Grade 213
Leukopenia - Grade 311
Leukopenia - Grade 41
Thrombocytopenia - Grade 115
Thrombocytopenia - Grade 25
Thrombocytopenia - Grade 32
Thrombocytopenia - Grade 44
Neutropenia - Grade 19
Neutropenia - Grade 26
Neutropenia - Grade 311
Neutropenia - Grade 49
Anemia - Grade 114
Anemia - Grade 217
Anemia - Grade 37
Anemia - Grade 40
Transfusion - Grade 10
Transfusion - Grade 21
Transfusion - Grade 30
Transfusion - Grade 40
Coagulation - Grade 10
Coagulation - Grade 21
Coagulation - Grade 30
Coagulation - Grade 40
Gastrointestinal - Grade 114
Gastrointestinal - Grade 214
Gastrointestinal - Grade 34
Gastrointestinal - Grade 40
Nausea/vomiting - Grade 115
Nausea/vomiting - Grade 27
Nausea/vomiting - Grade 34
Nausea/vomiting - Grade 40
Genitourinary - Grade 14
Genitourinary - Grade 20
Genitourinary - Grade 32
Genitourinary - Grade 40
Hepatic - Grade 12
Hepatic - Grade 22
Hepatic - Grade 31
Hepatic - Grade 40
Alopecia - Grade 17
Alopecia - Grade 25
Dermatologic - Grade 110
Dermatologic - Grade 210
Dermatologic - Grade 33
Dermatologic - Grade 40
Neurologic - Grade 112
Neurologic - Grade 21
Neurologic - Grade 34
Neurologic - Grade 41
SGOT - Grade 19
SGOT - Grade 24
SGOT - Grade 30
SGOT - Grade 40
Alkaline phosphatase - Grade 13
Alkaline phosphatase - Grade 23
Alkaline phosphatase - Grade 30
Alkaline phosphatase - Grade 40
Ocular - Grade 12
Ocular - Grade 23
Ocular - Grade 31
Ocular - Grade 40
Hemorrhage - Grade 12
Hemorrhage - Grade 20
Hemorrhage - Grade 31
Hemorrhage - Grade 40
Pulmonary - Grade 14
Pulmonary - Grade 21
Pulmonary - Grade 30
Pulmonary - Grade 40
Lymphopenia - Grade 11
Lymphopenia - Grade 20
Lymphopenia - Grade 30
Lymphopenia - Grade 40
Constitutional - Grade 117
Constitutional - Grade 214
Constitutional - Grade 35
Constitutional - Grade 42
Metabolic - Grade 120
Metabolic - Grade 29
Metabolic - Grade 34
Metabolic - Grade 40
Cardiovascular - Grade 13
Cardiovascular - Grade 20
Cardiovascular - Grade 30
Cardiovascular - Grade 40
Pain - Grade 18
Pain - Grade 26
Pain - Grade 31
Pain - Grade 41
Infection - Grade 12
Infection - Grade 25
Infection - Grade 35
Infection - Grade 40
Auditory - Grade 10
Auditory - Grade 22
Auditory - Grade 31
Auditory - Grade 40
Lymphatics - Grade 14
Lymphatics - Grade 21
Lymphatics - Grade 30
Lymphatics - Grade 41
Endocrine - Grade 12
Endocrine - Grade 20
Endocrine - Grade 30
Endocrine - Grade 40
Allergy - Grade 10
Allergy - Grade 21
Allergy - Grade 30
Allergy - Grade 40
SecondaryDuration of Response

The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause.

Time frame:
time of initial response until documented tumor progression (up to 44 months)
Reported as:
Median · months
Duration of Response
monthsPemetrexed
Duration of Response8.4 (2.8 to 30.4)
SecondaryProgression-Free Survival

Defined as the time from date of first dose to the first observation of disease progression, or death due to any cause.

Time frame:
baseline until documented tumor progression (up to 44 months)
Reported as:
Median · months
Progression-Free Survival
monthsPemetrexed
Progression-Free Survival3.0 (1.0 to 33.1)
SecondaryOverall Survival

Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact.

Time frame:
baseline until death from any cause up to 5-year follow-up
Reported as:
Median · months
Overall Survival
monthsPemetrexed
Overall Survival11.4 (1.6 to 34.4)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pemetrexed—12/48 (25%)47/48 (97.9%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventPemetrexed
VomitingGastrointestinal disorders3/48
DehydrationMetabolism and nutrition disorders3/48
Febrile neutropeniaBlood and lymphatic system disorders2/48
ThrombocytopeniaBlood and lymphatic system disorders2/48
NauseaGastrointestinal disorders2/48
PyrexiaGeneral disorders2/48
RashSkin and subcutaneous tissue disorders2/48
UrticariaSkin and subcutaneous tissue disorders2/48
AnaemiaBlood and lymphatic system disorders1/48
NeutropeniaBlood and lymphatic system disorders1/48
Most frequent other events
Showing 10 of 23
Most frequent other events
EventPemetrexed
AnemiaBlood and lymphatic system disorders38/48
ConstitutionalGeneral disorders38/48
LeukopeniaBlood and lymphatic system disorders36/48
NeutropeniaBlood and lymphatic system disorders35/48
MetabolicMetabolism and nutrition disorders33/48
GastrointestinalGastrointestinal disorders32/48
ThrombocytopeniaBlood and lymphatic system disorders26/48
Nausea/vomitingGastrointestinal disorders26/48
DermatologicSkin and subcutaneous tissue disorders23/48
NeurologicNervous system disorders18/48

Baseline characteristics

Age, Customized
Age, Customized(participants)Pemetrexed
<40 years1
40-49 years6
50-59 years14
60-69 years14
70-79 years11
>79 years2
Sex: Female, Male
Sex: Female, Male(Participants)Pemetrexed
Female48
Male0
Region of Enrollment
Region of Enrollment(participants)Pemetrexed
United States48
Cell Type
Cell Type(participants)Pemetrexed
Serous34
Clear Cell5
Mixed Epithelial6
Endometrioid1
Adenocarcinoma, Unspecified1
Undifferentiated Carcinoma1
Gynecologic Oncology Group Performance Status
Gynecologic Oncology Group Performance Status(participants)Pemetrexed
0 - Fully active30
1 - Ambulatory, Restricted Strenuous Activity15
2 - Ambulatory, No Work Activities3
Prior Chemotherapy
Prior Chemotherapy(participants)Pemetrexed
Yes48
No0
Prior Radiotherapy
Prior Radiotherapy(participants)Pemetrexed
Yes1
No47
Race/Ethnicity
Race/Ethnicity(participants)Pemetrexed
White47
Black1

1 further baseline measures are reported on the registry.

08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Philadelphia, Pennsylvania, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2004, a primary completion of Oct 2007 and a completion of May 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2009, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2007
First posted
Apr 18, 2007
Start
Sep 2004
Primary completionActual
Oct 2007
CompletionActual
May 2008
Results first posted
Aug 24, 2009
Last update
Dec 4, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00461786
First posted
Apr 18, 2007
Start date
Sep 2004
Primary completion
Oct 2007
Completion
May 2008
Results posted
Aug 24, 2009
Last update
Dec 4, 2009

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pemetrexed

Start the discussion